(Stroke. 1997;28:1821-1829.)
© 1997 American Heart Association, Inc.
Articles |
The Role of Blood Pressure and Aldosterone in the Production of Hemorrhagic Stroke in Captopril-Treated Hypertensive Rats
From the Division of Basic Medical Sciences, Memorial University, St John's, Newfoundland, Canada.
Correspondence and reprint requests to Dr J.S. Smeda, Division of Basic Medical Sciences, Rm H4354, Memorial University, Health Science Centre, St John's, Newfoundland, Canada A1B 3V6.
Background and Purpose We tested the hypothesis that the lowering of plasma aldosterone levels contributed to the antistroke effects of captopril treatment in Wistar Kyoto stroke-prone spontaneously hypertensive rats (SHRSP).
Methods The suppression of plasma aldosterone by captopril treatment (50 mg · kg–1 · d–1) was prevented by the subcutaneous infusion of aldosterone into captopril-treated SHRSP. We studied the effect this had on blood pressure (BP) and stroke development.
Results SHRSP fed a Japanese-style diet containing 4% NaCl developed hypertension and a 100% mortality associated with intracerebral hemorrhage by 14 weeks of age. Captopril treatment from 6 weeks of age did not lower the BP but increased survival past 35 weeks of age. Hydralazine treatment (40 to 80 mg/L of drinking water) lowered BP in SHRSP but was less effective than captopril in retarding stroke. Plasma aldosterone levels were elevated with age in SHRSP after 10 weeks and were higher in poststroke versus prestroke SHRSP. Captopril treatment suppressed plasma aldosterone. When we elevated plasma aldosterone in captopril-treated SHRSP to levels between those present in untreated pre- and poststroke SHRSP, the ability of captopril to retard stroke development was negated. The effects of aldosterone were mimicked by deoxycorticosterone (40 mg/kg, SC2 times/wk) but not by dexamethasone (0.1 mg · kg–1 · d–1, SC). Spironolactone treatment (20 mg · kg–1 · d–1, SC) of SHRSP reduced BP but had little effect on stroke development.
Conclusions Elevations in plasma aldosterone enhance stroke development within captopril-treated SHRSP through mechanisms that do not involve stimulation of mineralocorticoid receptors or the enhancement of hypertension. The antistroke effects of captopril treatment may be partially mediated through the suppression of plasma aldosterone.
Key Words: aldosterone • angiotensins • cerebral hemorrhage • captopril • rats
This article has been cited by other articles:
 |
|
 |
|
  T.-Y. Chun, P. N. Chander, J.-W. Kim, J. H. Pratt, and C. T. Stier Jr. Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E305 - E312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sonoyama, A. Greenstein, A. Price, K. Khavandi, and T. Heagerty Review: Vascular remodeling: implications for small artery function and target organ damage Therapeutic Advances in Cardiovascular Disease, December 1, 2007; 1(2): 129 - 137. [Abstract] [PDF]
|
|
|
|
 |
|
 K. A. Griffin, I. Abu-Amarah, M. Picken, and A. K. Bidani Renoprotection by ACE Inhibition or Aldosterone Blockade Is Blood Pressure-Dependent Hypertension, February 1, 2003; 41(2): 201 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Virdis, M. F. Neves, F. Amiri, E. Viel, R. M. Touyz, and E. L. Schiffrin Spironolactone Improves Angiotensin-Induced Vascular Changes and Oxidative Stress Hypertension, October 1, 2002; 40(4): 504 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ngarmukos and R. J. Grekin Nontraditional aspects of aldosterone physiology Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1122 - E1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Dorrance, H. L. Osborn, R. Grekin, and R. C. Webb Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R944 - R950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rocha, C. T. Stier Jr., I. Kifor, M. R. Ochoa-Maya, H. G. Rennke, G. H. Williams, and G. K. Adler Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy Endocrinology, October 1, 2000; 141(10): 3871 - 3878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Smeda, S. Vasdev, and S. R. King Effect of Poststroke Captopril Treatment on Mortality Associated with Hemorrhagic Stroke in Stroke-Prone Rats J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 569 - 575. [Abstract] [Full Text]
|
|
|
|
|
|
R. Rocha, P. N. Chander, A. Zuckerman, and C. T. Stier Jr. Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats Hypertension, January 1, 1999; 33(1): 232 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. A. Blezer, K. Nicolay, P. R. D. Bar, R. Goldschmeding, G. H. Jansen, H. A. Koomans, J. A. Joles, and F. M. Faraci Enalapril Prevents Imminent and Reduces Manifest Cerebral Edema in Stroke-Prone Hypertensive Rats • Editorial Comment Stroke, August 1, 1998; 29(8): 1671 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rocha, P. N. Chander, K. Khanna, A. Zuckerman, and C. T. Stier Jr. Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats Hypertension, January 1, 1998; 31(1): 451 - 458. [Abstract] [Full Text] [PDF]
|
|